MX2014004603A - Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo. - Google Patents

Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo.

Info

Publication number
MX2014004603A
MX2014004603A MX2014004603A MX2014004603A MX2014004603A MX 2014004603 A MX2014004603 A MX 2014004603A MX 2014004603 A MX2014004603 A MX 2014004603A MX 2014004603 A MX2014004603 A MX 2014004603A MX 2014004603 A MX2014004603 A MX 2014004603A
Authority
MX
Mexico
Prior art keywords
phenyl
amino
pyrazol
pyrimidin
chloro
Prior art date
Application number
MX2014004603A
Other languages
English (en)
Other versions
MX360191B (es
Inventor
Jinling Chen
Matthew S Deaver
Richard J Holl
Kalyan Nuguru
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of MX2014004603A publication Critical patent/MX2014004603A/es
Publication of MX360191B publication Critical patent/MX360191B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se revelan formas de dosificación sólidas que comprenden 2-amino-3-(4-(2-amino-6-( (R)-1-(4-cloro-2-(3-metil-1H pirazol-1-il) fenil) -2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)pr opanoato de (S)-etilo (telotristat), también como métodos para fabricarlas y composiciones útiles en su manufactura.
MX2014004603A 2011-10-17 2012-10-16 Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo. MX360191B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547894P 2011-10-17 2011-10-17
PCT/US2012/060338 WO2013059146A1 (en) 2011-10-17 2012-10-16 Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate

Publications (2)

Publication Number Publication Date
MX2014004603A true MX2014004603A (es) 2014-05-12
MX360191B MX360191B (es) 2018-10-24

Family

ID=47116458

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004603A MX360191B (es) 2011-10-17 2012-10-16 Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo.

Country Status (19)

Country Link
US (4) US20130172376A1 (es)
EP (2) EP3763374A1 (es)
JP (1) JP6203182B2 (es)
KR (1) KR102047788B1 (es)
CN (1) CN103987381B (es)
AU (1) AU2012326383B2 (es)
BR (1) BR112014009308B1 (es)
CA (1) CA2851862C (es)
DK (1) DK2753306T3 (es)
ES (1) ES2835722T3 (es)
HU (1) HUE051585T2 (es)
IL (1) IL231958B (es)
MX (1) MX360191B (es)
PL (1) PL2753306T3 (es)
PT (1) PT2753306T (es)
RU (1) RU2661402C2 (es)
SG (1) SG11201401583YA (es)
UA (1) UA114412C2 (es)
WO (1) WO2013059146A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CN106102877A (zh) 2014-03-28 2016-11-09 日本碍子株式会社 整体型分离膜结构体及其制造方法
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
WO2017169591A1 (ja) 2016-03-31 2017-10-05 日本碍子株式会社 多孔質支持体、多孔質支持体の製造方法、分離膜構造体及び分離膜構造体の製造方法
TW201818964A (zh) 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
EP3363798A1 (en) 2017-02-20 2018-08-22 Esteve Química, S.A. Amorphous form of telotristat etiprate
CN115023221B (zh) * 2019-12-31 2024-05-28 辉瑞英国研发有限公司 1-((2s,5r)-5-((7h-吡咯并[2,3-d]嘧啶-4-基)氨基)-2-甲基哌啶-1-基)丙-2-烯-1-酮的稳定立即释放片剂和胶囊制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
CO5070643A1 (es) * 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
WO2006135638A2 (en) * 2005-06-09 2006-12-21 Wyeth Tanaproget compositions containing ethinyl estradiol
EP1886670A1 (en) * 2006-07-05 2008-02-13 Teva Pharmaceutical Industries Ltd Pharmaceutical compositions of memantine
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
TWI439457B (zh) * 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
WO2010056992A1 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN102421434A (zh) * 2009-03-31 2012-04-18 利亘制药公司 治疗高血压和糖尿病肾病的二苯基磺酰胺内皮素和血管紧张素ii受体激动剂的口服制剂

Also Published As

Publication number Publication date
RU2014119866A (ru) 2015-11-27
CN103987381A (zh) 2014-08-13
EP2753306A1 (en) 2014-07-16
IL231958B (en) 2018-06-28
US20190000843A1 (en) 2019-01-03
US20130172376A1 (en) 2013-07-04
AU2012326383A1 (en) 2014-04-24
IL231958A0 (en) 2014-05-28
NZ623423A (en) 2016-04-29
CA2851862A1 (en) 2013-04-25
PT2753306T (pt) 2020-11-11
MX360191B (es) 2018-10-24
EP3763374A1 (en) 2021-01-13
AU2012326383B2 (en) 2017-07-27
PL2753306T3 (pl) 2021-04-06
US20150157632A1 (en) 2015-06-11
ES2835722T3 (es) 2021-06-23
WO2013059146A1 (en) 2013-04-25
KR20140081872A (ko) 2014-07-01
BR112014009308A2 (pt) 2017-04-11
JP2014532073A (ja) 2014-12-04
RU2661402C2 (ru) 2018-07-16
SG11201401583YA (en) 2014-09-26
US11406635B2 (en) 2022-08-09
HUE051585T2 (hu) 2021-03-01
JP6203182B2 (ja) 2017-09-27
CN103987381B (zh) 2017-07-04
KR102047788B1 (ko) 2019-11-22
US20210008068A1 (en) 2021-01-14
CA2851862C (en) 2020-04-14
UA114412C2 (uk) 2017-06-12
BR112014009308B1 (pt) 2022-05-03
DK2753306T3 (da) 2020-12-14
EP2753306B1 (en) 2020-09-23
NZ717137A (en) 2017-10-27

Similar Documents

Publication Publication Date Title
MX360191B (es) Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo.
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MY177742A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2012013274A (es) Novedosos derivados de la pirimidina.
PH12017502236A1 (en) 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors
MX2014000635A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak.
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
MX2010011006A (es) Nueva sal de un derivado de pirimidina.
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази

Legal Events

Date Code Title Description
FG Grant or registration